Crimean-Congo hemorrhagic fever (CCHF), caused by an orthonairovirus of the *Nairoviridae* family, is usually transmitted by bites of *Hyalomma* sp. ticks. Case-fatality rates vary from 10% to 40%. Most cases are reported from the Balkans, the Middle East, and Asia ([@R1]), but CCHF virus is now also found in *Hyalomma* ticks in Spain, where human CCHF cases have occurred ([@R2],[@R3]).

The earliest known case of CCHF in Kosovo was observed in 1954 ([@R4]). Since 1989, outbreaks have been seen every 4--5 years ([@R5]). CCHF is present in 50% of the Kosovar territory, especially the central and southwest, which is at low altitude, has a hot climate, and consists mainly of bush and farmland vegetation ([@R6]). The same study found a human CCHF seroprevalence in Kosovo of 24.3%, annual incidence of 0.49/100,000 population, and a case-fatality rate of 26.76% (for 1995--2009).

Incubation of CCHF may take up to 9 days. Signs and symptoms usually start 1--3 days after the tick bite and include sudden onset of fever, myalgia, neck stiffness, photophobia, vomiting, diarrhea, sore throat, agitation, and confusion; 2--4 days later, drowsiness and pain in the right upper quadrant of the abdomen may ensue. Other signs and symptoms include tachycardia, petechiae, and lymphadenopathy. Approximately 30% of patients die [\>]{.ul}5 days after disease onset or later, typically from bleeding or multiorgan failure ([@R5]).

We present a retrospective analysis of all 32 CCHF cases from the Infectious Diseases Hospital of Hasan Prishtina University (Prishtina, Kosovo) during May 2013--July 2016. We obtained a statement of approval from the Committee of Professional Ethics of the University Clinical Center of Kosovo (filed under no. 1555 on October 27, 2017).

The Study
=========

We analyzed records of 32 patients with CCHF and excerpted demographic patient data, case history, symptoms, clinical signs, laboratory results, and outcome. Viral loads had been determined by reverse transcription PCR (RT-PCR) using a RealStar CCHFV RT-PCR Kit version 1.0 (Altona Diagnostics, <http://www.altona-diagnostics.com>). We used SPSS software (IBM, <http://www.ibm.com/analytics/spss-statistics-software>) for statistical analysis; p values of [\<]{.ul}0.05 by χ^2^ test or logistical regression (2-sided where applicable) were considered significant.

Of the 32 patients, 27 were male and 5 female; 21 patients were from the municipality of Malisheva (district of Prizren) and 9 from municipalities west of Malisheva ([Figure 1](#F1){ref-type="fig"}). Median age was 40.5 years (range 0--75 years) ([Figure 2](#F2){ref-type="fig"}). Most patients were exposed to ticks during farming.
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Eleven patients died, including 1 vertically infected female newborn; 21 survived. The median duration between initial symptoms and hospital admission was 2.5 days (range 0--7 days). Neither χ^2^ testing nor regression analysis showed a relationship between the duration of symptoms at hospitalization (or at the start of ribavirin) and outcome.

Of the 6 patients who did not receive ribavirin, 2 died. Of the 26 patients who received intravenous ribavirin, 9 died. Ribavirin had no effect on outcome; however, the sample size was small. The median duration between the start of symptoms and administration of ribavirin was 3.5 days (range 1--12 days). Univariate regression (odds radio \[OR\] 13.3, 95% CI 1.3--134; p = 0.028) and χ^2^ testing (p = 0.055) suggested a possible association between starting ribavirin \<5 days after disease onset and an increased probability of death. However, this effect was not significant after controlling for viral load (p = 0.19).

Signs of central nervous system (CNS) impairment (coma, somnolence, fasciculations) and bleeding showed the strongest interdependence with clinical outcome ([Table 1](#T1){ref-type="table"}). A weaker interdependence was shown for jaundice, diarrhea, and hiccups. Among the laboratory parameters, a viral load \>1 × 10^8.5^ copies/mL, lactate dehydrogenase (LDH) \>2,200 U/mL, and leukocyte count \>7,700 cells/µL were associated with death. We saw a nonsignificant trend toward interdependence between platelet counts \<50,000/µL and death (p = 0.057). We found no association with outcome for aspartate aminotransferase, alanine aminotransferase, or other laboratory parameters (data not shown).

###### Interdependence between clinical and laboratory findings and outcome for patients with Crimean-Congo hemorrhagic fever, Kosovo, 2013--2016\*

  Finding                                                           χ^2^     p value
  ----------------------------------------------------------------- -------- ---------
  Significant interdependence with outcome, with Yates correction            
  Clinical findings                                                          
  Fasciculations                                                    14.0     \<0.001
  Coma                                                              13.2     \<0.001
  Somnolence                                                        6.5      0.010
  Hemoperitoneum                                                    10.4     0.001
  Bleeding gums                                                     8.8      0.003
  Hematemesis                                                       7.7      0.005
  Melena                                                            5.7      0.017
  Petechiae                                                         5.7      0.017
  Ecchymoses                                                        5.5      0.019
  Jaundice                                                          6.2      0.013
  Diarrhea                                                          5.7      0.017
  Hiccup                                                            4.0      0.046
  Laboratory findings                                                        
  Viral load \>1 × 10^8.5^/mL                                       18.5     \<0.001
  LDH \>2,200 U/mL                                                  9.56     0.002
  Leukocytes \>7,700/µL                                             7.4      0.006
  No interdependence with outcome, without Yates correction                  
  Clinical findings                                                          
  Vertigo                                                           2.26     0.133
  Hypertension                                                      1.97     0.160
  Anorexia                                                          1.72     0.189
  Nausea                                                            1.60     0.205
  Epistaxis                                                         0.90     0.340
  Vomiting                                                          0.74     0.388
  Joint pain                                                        0.74     0.388
  Sweating                                                          0.23     0.631
  Headache                                                          0.13     0.722
  Conjunctivitis                                                    0.13     0.722
  Muscular pain                                                     0.08     0.773
  Abdominal pain                                                    0.05     0.830
  Hypotension                                                       0.03     0.864
  Bradycardia                                                       \<0.01   0.968
  Laboratory findings                                                        
  ALT \>168 U/mL                                                    1.54     0.215
  AST \>147 U/mL                                                    1.47     0.225
  CK \>1,037 U/mL                                                   0.79     0.373
  Nonsignificant trend toward interdependence with outcome                   
  Platelets \<50,000/µL                                             3.68     0.055
  With Yates correction                                             3.63     0.057

\*ALT, alanine aminotransferase; AST, aspartate aminotransferase; CK, creatine kinase; LDH, lactate dehydrogenase.

Of the clinical signs and symptoms, CNS impairment and bleeding predicted death. The death risk increased 35-fold (p = 0.003) in the presence of coma and 27-fold (p = 0.001) with somnolence; CNS impairment was present in all 11 patients who died. For fasciculations, we could not calculate an OR because no patient with fasciculations survived. Hemoperitoneum increased the death risk 16.6-fold (p = 0.004). If 4 of 5 bleeding signs (bleeding gums, hematemesis, melena, petechiae, ecchymoses) were present, the death risk increased 24-fold (p = 0.008). Diarrhea increased the death risk 7.2-fold (p = 0.023).

In multivariate analysis, the effects of bleeding, CNS involvement, and diarrhea on death risk were dependent on viral load and LDH levels. The effect of bleeding signs on death risk was independent of the effects of somnolence and of diarrhea. The effect of somnolence, but not of diarrhea, on death risk was independent of bleeding.

We saw no influence on death risk with other signs or symptoms ([Table 2](#T2){ref-type="table"}). Ribavirin therapy did not influence death risk (OR 1.059; p = 0.952) in the small sample size.

###### Clinical and laboratory findings and their association with death in patients with Crimean-Congo hemorrhagic fever, Kosovo, 2013--2016\*

  Finding                                                       OR for death if present (95% CI)   p value
  ------------------------------------------------------------- ---------------------------------- ------------
  Clinical findings significantly associated with death                                            
  Coma                                                          35.0 (3.32--369)                   0.003
  Somnolence                                                    27.0 (3.80--192)                   0.001
  Fasciculations†                                               NA (25.2 \[2.45--259\])            NA (0.007)
  Hemoperitoneum                                                16.6 (2.47--112)                   0.004
  Hematemesis                                                   11.4 (1.74--74.7)                  0.011
  Bleeding gums                                                 11.3 (2.04--63.1)                  0.006
  Ecchymoses                                                    7.31 (1.25--42.8)                  0.027
  Melena                                                        7.20 (1.31--39.6)                  0.023
  Petechiae                                                     6.67 (1.31--34.0)                  0.023
  [\>]{.ul}4 of the 5 previous findings                         24.0 (2.33--247)                   0.008
  Diarrhea                                                      7.20 (1.31--39.6)                  0.023
  Jaundice†                                                     NA (7.87 \[0.71--87.3\])           NA (0.093)
  Clinical findings not significantly associated with death                                        
  Vertigo                                                       5.00 (0.53--47.3)                  0.160
  Female sex                                                    3.56 (0.50--25.6)                  0.206
  Epistaxis                                                     2.08 (0.46--9.51)                  0.343
  Sweats                                                        2.00 (0.11--35.4)                  0.636
  Joint pain                                                    1.92 (0.43--8.61)                  0.391
  Headache                                                      1.31 (0.29--5.89)                  0.723
  Conjunctivitis                                                1.31 (0.29--5.89)                  0.723
  Abdominal pain                                                1.20 (0.23--6.34)                  0.830
  Tiredness                                                     1.05 (0.08--13.1)                  0.968
  Bradycardia                                                   1.05 (0.08--13.1)                  0.968
  Metrorrhagia                                                  0.95 (0.08--11.1)                  0.968
  Hypotension                                                   0.87 (0.19--4.03)                  0.864
  Muscular pain                                                 0.75 (0.11--5.32)                  0.774
  Vomiting                                                      0.52 (0.12--2.32)                  0.391
  Hyperemia                                                     0.42 (0.09--1.86)                  0.251
  Anorexia                                                      0.28 (0.04--2.01)                  0.206
  Nausea                                                        0.25 (0.03--2.40)                  0.230
  Hiccup†                                                       NA (4.67 \[0.37--58.3\])           NA (0.232)
  Hypertension†                                                 NA (2.10 \[0.12--37.1\])           NA (0.613)
  Ribavirin not given                                           1.059 (0.162--6.94)                0.952
  Laboratory findings significantly associated with death                                          
  VL \>1 × 10^8.5^                                              80.0 (6.3--1,011)                  0.001
  LDH \>3,500 U/L†                                              NA (26.7 \[2.24--317\])            NA (0.009)
  LDH \>2,700 U/L                                               37.5 (2.77--507)                   0.006
  Leukocytes \>7.7                                              15.8 (1.53--164)                   0.020
  Leukocytes \>8.0†                                             NA (16.7 \[1.62--172\])            NA (0.018)
  Platelets \<50.000/µL                                         5.25 (1.07--25.8)                  0.041
  Laboratory findings not significantly associated with death                                      
  ALT \>168 U/L                                                 3.20 (0.48--21.2)                  0.228
  AST \>147 U/L                                                 2.75 (0.52--14.4)                  0.232
  CK \>1,037                                                    1.95 (0.44--8.55)                  0.376
  IgG \<2.5‡                                                    NA (4.67 \[0.45--48.3\])           NA (0.196)
  IgM \<2.5‡                                                    NA (4.67 \[0.45--48.3\])           NA (0.196)

\*ALT, alanine aminotransferase; AST, aspartate aminotransferase; CK, creatine kinase; LDH, lactate dehydrogenase; NA, not applicable; OR, odds ratio; VL, viral load. †The OR could not be determined because there were no survivors with this symptom. The value in parentheses would have been obtained if 1 hypothetical survivor had this symptom or test result. ‡The OR could not be determined because there were no deaths among patients with this finding. The value in parentheses would have been obtained if 1 hypothetical fatal case had this test result.

The strongest predictor of death was a viral load \>1 × 10^8.5^ viral copies/mL of serum (OR 80.0; p = 0.001), followed by an LDH \>2,700 U/mL (OR 37.5; p = 0.006). The probability of death was also increased for leukocyte counts \>7,700 cells/µL (OR 37.5; p = 0.006) and platelet counts \<50,000/µL (OR 5.25; p = 0.041).

In multivariate analysis, viral loads \>1 × 10^8.5^ copies/mL and LDH levels \>2,700 U/mL independently increased the probability of death ([Table 2](#T2){ref-type="table"}). However, the effect of leukocyte counts \>7,700 cells/µL and platelet counts \<50,000/µL did not persist when controlled for viral loads or LDH levels. No other routine laboratory parameters, including hemoglobin, creatine kinase, aspartate aminotransferase, alanine aminotransferase, prothrombin time, partial thromboplastin time, CCHF virus IgG, and CCHF IgM virus, predicted the outcome in the patients we analyzed.

Conclusions
===========

Our results showed that the strongest clinical predictors of death from CCHF were bleeding and neurologic involvement. We saw somnolence or coma in all 11 fatal cases and bleeding in 9. In 2 patients, intracerebral bleeding could not be excluded because computed tomography or magnetic resonance imaging scans were not available. Therefore, the question whether all fatal neurologic complications in CCHF are caused by hemorrhage remains open.

Of laboratory parameters, the strongest predictors of death were viral load \>1 × 10^8.5^ viral genome copies/mL (OR 80) and LDH level \>2,700 U/mL (OR 37.5). The predictive value of viral load has been described in Kosovo and Turkey ([@R7],[@R8]). High viral loads predicted high LDH levels, which in turn predicted complications and death. CCHF virus infection may induce organ failure by causing apoptosis of several cell types of endothelial and parenchymal origin ([@R9]). Other factors probably contribute to CCHF pathology also.

We saw a higher case-fatality rate in Kosovo (34%) than that reported in Turkey (11%) ([@R8]). Although the virus clade circulating in Kosovo was probably introduced from Turkey in the 1970s, it is possible that the high genetic viral diversity found in fatal CCHF cases in Kosovo increases CCHF pathogenicity ([@R10]).

Our study did not detect any benefit of intravenous ribavirin for CCHF; however, even a recent Cochrane meta-analysis has not answered the question whether ribavirin is beneficial in CCHF ([@R11]). A murine treatment study suggests that ribavirin is insufficiently effective even when given before disease onset ([@R12]). To improve the prognosis for CCHF, new antiviral substances that effectively curb virus replication are needed.
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